Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription Articles published in Eur Urol Retrieve available abstracts of 255 articles: HTML format

Single Articles

April 2024
1. BABJUK M
   Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
   Eur Urol. 2024 Apr 9:S0302-2838(24)02262-0. doi: 10.1016/j.eururo.2024.
   PubMed    
   
   
   
2. LIEDBERG F, Bobjer J
   Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
   Eur Urol. 2024;85:392.
   PubMed    
   
   
   
3. LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
   The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
   Eur Urol. 2024;85:317-319.
   PubMed     Abstract available
   
   
   
4. DAHM P, Ergun O, Sathianathen N
   Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Contr
   Eur Urol. 2024;85:e116.
   PubMed    
   
   
   
5. PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
   Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.
   Eur Urol. 2024;85:348-360.
   PubMed     Abstract available
   
   
   
6. COX A, Klumper N, Stein J, Sikic D, et al
   Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
   Eur Urol. 2024;85:328-332.
   PubMed     Abstract available
   
   
   March 2024
7. DUQUESNE I, de la Taille A
   Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
   Eur Urol. 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
   PubMed    
   
   
   
8. ZHOU Y, D'Andrea VD, Shanmugam SP, Stelter I, et al
   Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
   Eur Urol. 2024 Mar 23:S0302-2838(24)02231-0. doi: 10.1016/j.eururo.2024.
   PubMed    
   
   
   
9. ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
   Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
   Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
   PubMed    
   
   
   
10. GUPTA S, Necchi A
    LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
    Eur Urol. 2024;85:239-241.
    PubMed    
    
    
    
11. HUELSTER HL, Gould B, Schiftan EA, Camperlengo L, et al
    Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
    Eur Urol. 2024;85:283-292.
    PubMed     Abstract available
    
    
    
12. MATSUBARA N, de Wit R, Balar AV, Siefker-Radtke AO, et al
    Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Eur Urol. 2024;85:229-238.
    PubMed     Abstract available
    
    
    
13. HEER R, Tan WS, Gravestock P, Vadiveloo T, et al
    Reply to Arnulf Stenzl, Morgan Roupret, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
    Eur Urol. 2024;85:309-312.
    PubMed    
    
    
    
14. CAVILLON A, Pouessel D, Houede N, Mathevet F, et al
    Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
    Eur Urol. 2024;85:293-300.
    PubMed     Abstract available
    
    
    February 2024
15. VAN DER KWAST TH, Bubendorf L, Cheng L
    International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations.
    Eur Urol. 2024 Feb 26:S0302-2838(24)00080-0. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
16. MOSCHINI M, Necchi A, Montorsi F
    Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
17. SHARIAT SF, Laukhtina E
    Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34.
    Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
18. NAOUN N, Loriot Y
    Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
    Eur Urol. 2024;85:123-124.
    PubMed    
    
    
    
19. SRIDHAR SS, Powles T, Climent Duran MA, Park SH, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Eur Urol. 2024;85:154-163.
    PubMed     Abstract available
    
    
    
20. POWLES T, Assaf ZJ, Degaonkar V, Grivas P, et al
    Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Eur Urol. 2024;85:114-122.
    PubMed     Abstract available
    
    
    January 2024
21. BINHUMAID FS, Goel A, Gordon NS, Abbotts B, et al
    Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients.
    Eur Urol. 2024 Jan 31:S0302-2838(24)00017-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
22. KIM SK, Byun YJ, Park SH, Piao XM, et al
    A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Jan 11:S0302-2838(24)00001-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
23. PEDERZOLI F, Riba M, Venegoni C, Marandino L, et al
    Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Jan 5:S0302-2838(23)03341-9. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
24. XIE Q, Shen D
    Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
    Eur Urol. 2024;85:e17-e18.
    PubMed    
    
    
    
25. PRASAD RAI B, Violette PD, Imran Omar M
    Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with H
    Eur Urol. 2024;85:e15-e16.
    PubMed    
    
    
    December 2023
26. YOLMO P, Siemens DR, Koti M
    Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 23:S0302-2838(23)03296-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
27. BECKABIR W, Wobker SE, Damrauer JS, Midkiff B, et al
    Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
28. FENG YN, Xie GY, Xiao L
    Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
    Eur Urol. 2023;84:e145.
    PubMed    
    
    
    
29. PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
    Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Blad
    Eur Urol. 2023;84:e154.
    PubMed    
    
    
    
30. LI DX, Feng DC, Deng S
    Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-gui
    Eur Urol. 2023;84:e152-e153.
    PubMed    
    
    
    November 2023
31. KLUMPER N, Eckstein M, Holzel M, Herrmann K, et al
    Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT.
    Eur Urol. 2023;84:514-515.
    PubMed    
    
    
    
32. MEEKS JJ, Black PC, Galsky M, Grivas P, et al
    Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
    Eur Urol. 2023;84:473-483.
    PubMed     Abstract available
    
    
    
33. MARTINI A, Falagario UG, Russo A, Mertens LS, et al
    Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
    Eur Urol. 2023;84:484-490.
    PubMed     Abstract available
    
    
    October 2023
34. WANG Z, Zeng S, Xu C
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
35. HENSLEY PJ, Choudhury A, Khaki AR, Grivas P, et al
    The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
36. SEISEN T, Roupret M, Trinh QD, Bellmunt J, et al
    Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J
    Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
37. SWINTON M, Hoskin P, Choudhury A
    Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alterna
    Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
38. ALFRED WITJES J, Max Bruins H, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
    Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
39. KULKARNI GS, Wettstein MS
    SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
40. KHETRAPAL P, Wong JKL, Tan WP, Rupasinghe T, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials.
    Eur Urol. 2023;84:393-405.
    PubMed     Abstract available
    
    
    September 2023
41. FENG M, Matoso A, Epstein G, Fong M, et al
    Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
    Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
42. STRANDGAARD T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, et al
    Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer.
    Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
43. INAMURA K
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
44. ZLOTTA AR, Lajkosz K, Efstathiou JA
    Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institut
    Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    August 2023
45. SEISEN T, Roupret M, Blanchard P
    Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
46. BLACK PC, Tangen CM, Singh P, McConkey DJ, et al
    Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
47. SUSSMAN J, Konety B, Ahmadi H
    Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
    Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    July 2023
48. BASILE G, Audenet F, Seisen T, Pradere B, et al
    The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials.
    Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
49. CIGLIOLA A, Mercinelli C, Patane D, Raggi D, et al
    Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
    Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
50. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
51. LABAKI C, Saad E, Choueiri TK, Bellmunt J, et al
    Oligometastatic Bladder Cancer: Defining a Novel Entity.
    Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
52. GRIVAS P, Park SH, Voog E, Caserta C, et al
    Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Eur Urol. 2023;84:95-108.
    PubMed     Abstract available
    
    
    
53. ROUPRET M, Seisen T, Birtle AJ, Capoun O, et al
    European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
    Eur Urol. 2023;84:49-64.
    PubMed     Abstract available
    
    
    
54. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
    Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
    Eur Urol. 2023;84:117-126.
    PubMed     Abstract available
    
    
    
55. KOTI M, Robert Siemens D
    A Step Closer to Predicting Progression After Bacillus Calmette-Guerin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    June 2023
56. FENG M, Matoso A, Epstein G, Fong M, et al
    Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
57. GROENEVELD CS, Sanchez-Quiles V, Dufour F, Shi M, et al
    Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
58. BORREGALES LD, Venkat S, Posada Calderon L, Lewicki P, et al
    A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
59. O'CALLAGHAN M
    Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial.
    Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
60. MOSCHINI M, Montorsi F
    Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors.
    Eur Urol. 2023;83:582.
    PubMed    
    
    
    
61. LAUKHTINA E, Shariat SF
    Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    May 2023
62. MAKAROFF LE, Filicevas A, Boldon S, Hensley P, et al
    Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
    Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
63. BAMIAS A, Stenzl A, Brown SL, Albiges L, et al
    Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
    Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
64. KOUTROS S, Kiemeney LA, Pal Choudhury P, Milne RL, et al
    Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
    Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
65. JUBBER I, Ong S, Bukavina L, Black PC, et al
    Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
    Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
66. GALSKY MD, Bajorin DF, Witjes JA, Gschwend JE, et al
    Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
    Eur Urol. 2023;83:432-440.
    PubMed     Abstract available
    
    
    April 2023
67. LENFANT L, Pinar U, Roupret M, Seisen T, et al
    Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
    Eur Urol. 2023 Apr 17:S0302-2838(23)02714-8. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
68. MOLINA GE, Schwartz B, Srinivas S, Shah S, et al
    In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
    Eur Urol. 2023;83:377-378.
    PubMed    
    
    
    
69. BERGEROT CD, Gupta S
    Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
    Eur Urol. 2023;83:329-330.
    PubMed    
    
    
    
70. GRIVAS P, Kopyltsov E, Su PJ, Parnis FX, et al
    Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Eur Urol. 2023;83:320-328.
    PubMed     Abstract available
    
    
    March 2023
71. MOSCHINI M, Salonia A, Briganti A, Montorsi F, et al
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    Eur Urol. 2023 Mar 24:S0302-2838(23)02649-0. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
72. CHENG C, Hu J, Chen J
    Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
    Eur Urol. 2023 Mar 24:S0302-2838(23)02653-2. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
73. CERRATO C, Roupret M, Mir MC
    Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
    Eur Urol. 2023 Mar 23:S0302-2838(23)02643-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
74. LENFANT L, Pinar U, Roupret M, Seisen T, et al
    First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?
    Eur Urol. 2023 Mar 18:S0302-2838(23)02637-4. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
75. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
    Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
    Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
76. MAITRE P, Sangar V, Choudhury A
    ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
77. STENZL A, Roupret M, Witjes JA, Gontero P, et al
    High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
    Eur Urol. 2023;83:193-194.
    PubMed     Abstract available
    
    
    February 2023
78. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
    Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
79. DE ANGELIS M, Briganti A, Montorsi F, Moschini M, et al
    Re: A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Feb 16:S0302-2838(23)02571-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
80. ERLMEIER F, Klumper N, Landgraf L, Strissel PL, et al
    Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
    Eur Urol. 2023;83:133-142.
    PubMed     Abstract available
    
    
    
81. PEDERSEN GL, Erikson MS, Mogensen K, Rosthoj S, et al
    Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A P
    Eur Urol. 2023;83:125-130.
    PubMed     Abstract available
    
    
    
82. SUDERMAN J, St-Laurent MP, Black PC
    Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Feb 1:S0302-2838(23)00016-7. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    January 2023
83. HAHN NM, O'Donnell MA, Efstathiou JA, Zahurak M, et al
    A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
    Eur Urol. 2023 Jan 28:S0302-2838(23)00025-8. doi: 10.1016/j.eururo.2023.
    PubMed     Abstract available
    
    
    
84. PRADERE B, Basile G, Seisen T
    Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjot, Jorgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a
    Eur Urol. 2023 Jan 28:S0302-2838(23)00024-6. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
85. PAOLO G, Francesco S
    Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00014-3. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
86. LINDGREN MS, Jensen JB
    Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen's Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjot, Jorgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chem
    Eur Urol. 2023 Jan 27:S0302-2838(23)00023-4. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
87. BASILE G, Bandini M, Montorsi F, Necchi A, et al
    Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Foll
    Eur Urol. 2023 Jan 25:S0302-2838(23)00021-0. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
88. KLUMPER N, Holzel M, Eckstein M
    Reply to Jon Griffin. TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2023 Jan 24:S0302-2838(23)00022-2. doi: 10.1016/j.eururo.2023.
    PubMed    
    
    
    
89. QUAN C, Chen J, Hu J
    Re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14.
    Eur Urol. 2023 Jan 24:S0302-2838(23)00020-9. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
90. ST-LAURENT MP, Suderman J, Black PC
    Re: A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jan 3:S0302-2838(22)02866-4. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
91. SHI MJ, Fontugne J, Moreno-Vega A, Meng XY, et al
    FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Eur Urol. 2023;83:70-81.
    PubMed     Abstract available
    
    
    
92. VIGNANI F, Tambaro R, De Giorgi U, Giannatempo P, et al
    Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
    Eur Urol. 2023;83:82-89.
    PubMed     Abstract available
    
    
    
93. EINERHAND SMH, van Dorp J, van der Heijden MS, van Rhijn BWG, et al
    Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma.
    Eur Urol. 2023;83:91-92.
    PubMed    
    
    
    
94. KARTOLO A, Robinson A, Vera Badillo FE
    Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?
    Eur Urol. 2023;83:1-2.
    PubMed     Abstract available
    
    
    December 2022
95. LIEDBERG F, Tragardh E
    Re: Laura S. Mertens, Richard P. Meijer, J. Alfred Witjes. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.017.
    Eur Urol. 2022 Dec 8:S0302-2838(22)02842-1. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
96. ZHAO Z, Guo H, Yang R
    Re: Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 2022;82:212-22.
    Eur Urol. 2022;82:e176.
    PubMed    
    
    
    November 2022
97. BABJUK M
    Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study.
    Eur Urol. 2022 Nov 30:S0302-2838(22)02830-5. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
98. TAN WS, Mustard C, Kelly JD
    Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Pat
    Eur Urol. 2022 Nov 28:S0302-2838(22)02793-2. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
99. GRIFFIN J
    TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Nov 25:S0302-2838(22)02795-6. doi: 10.1016/j.eururo.2022.
    PubMed    
    
    
    
100. STEINBERG RL, O'Donnell MA, Packiam VT
     Re: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin. Eur Urol. 2022;82:602-10.
     Eur Urol. 2022 Nov 17:S0302-2838(22)02781-6. doi: 10.1016/j.eururo.2022.
     PubMed    
     
     
     
101. SAHOO S, Pandey A, Mandal S, Kumar Das M, et al
     Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Con
     Eur Urol. 2022 Nov 17:S0302-2838(22)02783-X. doi: 10.1016/j.eururo.2022.
     PubMed    
     
     
     
102. CAMPODONICO F, Mattioli F, Introini C
     Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Co
     Eur Urol. 2022 Nov 10. pii: S0302-2838(22)02778.
     PubMed    
     
     
     
103. XU P, Chen C, Chen B, Bi E, et al
     Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre.
     Eur Urol. 2022;82:543-550.
     PubMed     Abstract available
     
     
     
104. LONATI C, Suardi N
     Re: Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.
     Eur Urol. 2022;82:574.
     PubMed    
     
     
     
105. MONTIRONI R, Cimadamore A
     Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity.
     Eur Urol. 2022;82:483-486.
     PubMed    
     
     
     October 2022
106. TAN WS, Kelly JD
     Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-
     Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02719.
     PubMed    
     
     
     
107. ZLOTTA AR
     Re: Management, Surveillance Patterns, and Costs Associated with Low-grade Papillary Stage Ta Non-muscle-invasive Bladder Cancer Among Older Adults, 2004-2013.
     Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02711.
     PubMed    
     
     
     
108. STENZL A
     Re. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial.
     Eur Urol. 2022 Oct 14. pii: S0302-2838(22)02706.
     PubMed    
     
     
     
109. STRANDGAARD T, Lindskrog SV, Nordentoft I, Christensen E, et al
     Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guerin Failure in Patients with Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2022 Oct 6. pii: S0302-2838(22)02636.
     PubMed     Abstract available
     
     
     
110. MERTENS LS, Meijer RP, Alfred Witjes J
     Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy.
     Eur Urol. 2022 Oct 3. pii: S0302-2838(22)02691.
     PubMed     Abstract available
     
     
     
111. MIRON B, Geynisman DM
     Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
     Eur Urol. 2022;82:374-376.
     PubMed    
     
     
     
112. SIEFKER-RADTKE AO, Cho DC, Diab A, Sznol M, et al
     Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
     Eur Urol. 2022;82:365-373.
     PubMed     Abstract available
     
     
     September 2022
113. SRIDHAR SS, North SA, Blais N
     Predictive Biomarkers in Muscle Invasive Bladder Cancer: Are We There Yet?
     Eur Urol. 2022 Sep 22. pii: S0302-2838(22)02631.
     PubMed    
     
     
     
114. ROCCO B, Sighinolfi MC
     Re: James W.F. Catto, Pramit Khetrapal, Federico Ricciardi, et al. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Ran
     Eur Urol. 2022 Sep 22. pii: S0302-2838(22)02626.
     PubMed    
     
     
     
115. TAYLOR J, Lotan Y
     Is Office-based Management of Intermediate-risk Low-grade Non-muscle-invasive Bladder Cancer Ready For Prime Time?
     Eur Urol. 2022 Sep 21. pii: S0302-2838(22)02629.
     PubMed    
     
     
     
116. HAYNE D, Redfern A
     The Evolving Role of Locally Delivered Checkpoint Inhibitors in Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2022 Sep 21. pii: S0302-2838(22)02623.
     PubMed    
     
     
     
117. CATTO JWF, Khetrapal P, Ambler G, Williams NR, et al
     Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: James W.F. Catto, Pramit Khetrapal, Federico Ricciardi, et al. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy
     Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02627.
     PubMed    
     
     
     
118. KAVOUSSI M, Nasrallah AA, Williams SB
     Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guerin-naive High-risk Nonmuscle-invasive Bladder Cancer.
     Eur Urol. 2022 Sep 8. pii: S0302-2838(22)02615.
     PubMed    
     
     
     
119. SUAREZ-CABRERA C, Estudillo L, Ramon-Gil E, Martinez-Fernandez M, et al
     BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up.
     Eur Urol. 2022 Sep 6. pii: S0302-2838(22)02562.
     PubMed    
     
     
     
120. NAKAUMA-GONZALEZ JA, Rijnders M, van de Werken HJG, Lolkema MPJ, et al
     Reply to Yuxuan Song, Caipeng Qin, and Tao Xu's Letter to the Editor re: J. Alberto Nakauma-Gonzalez, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Car
     Eur Urol. 2022;82:e78-e79.
     PubMed    
     
     
     
121. SONG Y, Qin C, Xu T
     Re: J. Alberto Nakauma-Gonzalez, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6: Novel Insights into Evidence of Metas
     Eur Urol. 2022;82:e76-e77.
     PubMed    
     
     
     
122. GHATALIA P, Plimack ER
     Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder Cancer.
     Eur Urol. 2022 Sep 1. pii: S0302-2838(22)02584.
     PubMed    
     
     
     August 2022
123. MEGHANI K, Cooley LF, Choy B, Kocherginsky M, et al
     First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin.
     Eur Urol. 2022 Aug 22. pii: S0302-2838(22)02553.
     PubMed     Abstract available
     
     
     
124. TAN WS, Prendergast A, Ackerman C, Yogeswaran Y, et al
     Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
     Eur Urol. 2022 Aug 20. pii: S0302-2838(22)02552.
     PubMed     Abstract available
     
     
     
125. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
     Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
     Eur Urol. 2022 Aug 11. pii: S0302-2838(22)02538.
     PubMed     Abstract available
     
     
     
126. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
     Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
     Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
     PubMed    
     
     
     
127. CATTO JWF, Khetrapal P, Ambler G, Williams NR, et al
     Reply to Andreas Skolarikos's Words of Wisdom re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical
     Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02535.
     PubMed    
     
     
     
128. SONG Y, Du Y, Xu T
     Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
     Eur Urol. 2022 Aug 5. pii: S0302-2838(22)02530.
     PubMed    
     
     
     
129. SKOLARIKOS A
     Re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial.
     Eur Urol. 2022 Aug 3. pii: S0302-2838(22)02525.
     PubMed    
     
     
     
130. DE RUITER BM, van Hattum JW, Lipman D, de Reijke TM, et al
     Phase 1 Study of Chemoradiotherapy Combined with Nivolumab +/- Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
     Eur Urol. 2022 Aug 3. pii: S0302-2838(22)02522.
     PubMed     Abstract available
     
     
     
131. SZABADOS B, Kockx M, Assaf ZJ, van Dam PJ, et al
     Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
     Eur Urol. 2022;82:212-222.
     PubMed     Abstract available
     
     
     
132. RAI BP, Luis Dominguez Escrig J, Vale L, Kuusk T, et al
     Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.
     Eur Urol. 2022;82:182-192.
     PubMed     Abstract available
     
     
     July 2022
133. TAKAHASHI T
     Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.o
     Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02466.
     PubMed    
     
     
     
134. ADELEKE S, Tocco B, Kasivisvanathan V
     Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.
     Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02470.
     PubMed    
     
     
     June 2022
135. HANEY CM, Kriegmair MC, Michel MS, Stolzenburg JU, et al
     New Evidence and Innovative Approaches to Blinding in Robot-assisted Radical Cystectomy.
     Eur Urol. 2022;81:615-617.
     PubMed    
     
     
     
136. PEEKER R
     Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
     Eur Urol. 2022;81:619-620.
     PubMed    
     
     
     May 2022
137. SOLANKI AA, Kates MR, Tran PT
     Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001.
     Eur Urol. 2022 May 28. pii: S0302-2838(22)02343.
     PubMed    
     
     
     
138. RADZISZEWSKI P, Szablonski W
     Re: Bladder Cancer in Patients Younger than 40 Years: Outcomes from the National Cancer Database de la Calle CM, Washington SL 3rd, Lonergan PE, et al World J Urol 2021;39:1911-6.
     Eur Urol. 2022 May 19. pii: S0302-2838(22)01812.
     PubMed    
     
     
     
139. HALL E, Hussain SA, Porta N, Lewis R, et al
     Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
     Eur Urol. 2022 May 13. pii: S0302-2838(22)02265.
     PubMed     Abstract available
     
     
     
140. CONROY S, Nguyen AHT
     Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer.
     Eur Urol. 2022 May 5. pii: S0302-2838(22)01811.
     PubMed    
     
     
     
141. MCGREGOR B, O'Donnell PH, Balar A, Petrylak D, et al
     Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
     Eur Urol. 2022;81:515-522.
     PubMed     Abstract available
     
     
     
142. GEAVLETE P, Multescu R, Geavlete B
     Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19?
     Eur Urol. 2022;81:543.
     PubMed    
     
     
     
143. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
     Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
     Eur Urol. 2022;81:523-532.
     PubMed     Abstract available
     
     
     April 2022
144. LAUKHTINA E, Shariat SF
     Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
     Eur Urol. 2022 Apr 30. pii: S0302-2838(22)01816.
     PubMed    
     
     
     
145. ERTL IE, Lemberger U, Ilijazi D, Hassler MR, et al
     Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
     Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01678.
     PubMed     Abstract available
     
     
     
146. GALLIOLI A, Breda A, Palou J
     Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
     Eur Urol. 2022;81:428-429.
     PubMed    
     
     
     
147. NAKAUMA-GONZALEZ JA, Rijnders M, van Riet J, van der Heijden MS, et al
     Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
     Eur Urol. 2022;81:331-336.
     PubMed     Abstract available
     
     
     March 2022
148. MAYR R, Eckstein M, Wirtz RM, Santiago-Walker A, et al
     Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy.
     Eur Urol. 2022 Mar 26. pii: S0302-2838(22)01670.
     PubMed     Abstract available
     
     
     
149. ALFRED WITJES J
     Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study.
     Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01786.
     PubMed    
     
     
     
150. WEINSTOCK C, Agrawal S, Chang E
     Optimizing Clinical Trial Design for Patients with Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2022 Mar 15. pii: S0302-2838(22)01655.
     PubMed    
     
     
     
151. HENSLEY PJ, Kamat AM
     Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
     Eur Urol. 2022;81:316-317.
     PubMed    
     
     
     
152. CLEMENTS MB, Atkinson TM, Dalbagni GM, Li Y, et al
     Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.
     Eur Urol. 2022;81:294-304.
     PubMed     Abstract available
     
     
     February 2022
153. HUNG SF, Yii SC, Chung SD
     Re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eur
     Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00077.
     PubMed    
     
     
     
154. PARIKH DA, Khaki AR, Williams SB
     Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
     Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00017.
     PubMed    
     
     
     
155. HE P, Zhou X, Chen Z
     Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung's Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligament
     Eur Urol. 2022 Feb 3. pii: S0302-2838(22)00081.
     PubMed    
     
     
     
156. RUTKA JT, Fleshner N, Nathens AB
     Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9.
     Eur Urol. 2022;81:e51.
     PubMed    
     
     
     January 2022
157. BRAUN A, Abbosh PH
     Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
     Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
     PubMed    
     
     
     
158. BABJUK M
     Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
     Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00023.
     PubMed    
     
     
     
159. GROBET-JEANDIN E, Pinar U, Roupret M
     Re: Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
     Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00012.
     PubMed    
     
     
     
160. RENTSCH CA, Hayoz S, Cathomas RL
     Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study.
     Eur Urol. 2022 Jan 24. pii: S0302-2838(22)00022.
     PubMed    
     
     
     
161. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
     Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://do
     Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02284.
     PubMed    
     
     
     
162. DE JONG JJ, Gibb EA
     Re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035: Neoadjuvant Chemotherapy Resp
     Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02281.
     PubMed    
     
     
     
163. GROBET-JEANDIN E, Pinar U, Roupret M
     Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16-7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer:
     Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02282.
     PubMed    
     
     
     
164. CARMEN MIR M, Greenwell T, O'Kelly F, Proietti S, et al
     Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
     Eur Urol. 2022;81:e26-e27.
     PubMed    
     
     
     
165. CATHOMAS R, Lorch A, Bruins HM, Comperat EM, et al
     The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
     Eur Urol. 2022;81:95-103.
     PubMed     Abstract available
     
     
     
166. SAAD S, Osman NI, Chapple CR
     Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
     Eur Urol. 2022;81:e16-e17.
     PubMed    
     
     
     
167. LIEDBERG F, Abrahamsson J, Bobjer J
     Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/
     Eur Urol. 2022;81:e18-e19.
     PubMed    
     
     
     
168. SHIGETA K, Matsumoto K, Oya M
     Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract Urothelial
     Eur Urol. 2022;81:e20-e21.
     PubMed    
     
     
     
169. DEV S
     Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
     Eur Urol. 2022;81:e25.
     PubMed    
     
     
     December 2021
170. ROUMIGUIE M, Kamat AM, Bivalacqua TJ, Lerner SP, et al
     International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2021 Dec 23. pii: S0302-2838(21)02213.
     PubMed     Abstract available
     
     
     
171. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
     Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
     Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
     PubMed     Abstract available
     
     
     
172. MITRA AP, Narayan VM, Mokkapati S, Miest T, et al
     Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
     Eur Urol. 2021 Dec 18. pii: S0302-2838(21)02217.
     PubMed     Abstract available
     
     
     November 2021
173. CHEN Z, He P, Zhou X, Li P, et al
     Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer.
     Eur Urol. 2021 Nov 30. pii: S0302-2838(21)02160.
     PubMed     Abstract available
     
     
     
174. REIKE MJ, Adar R, Black PC
     Not "If", but "When" and "How": Testing Antibody-Drug Conjugates in Patients with Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2021 Nov 24. pii: S0302-2838(21)02151.
     PubMed    
     
     
     
175. BURDETT S, Fisher DJ, Vale CL, Bono AV, et al
     Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
     Eur Urol. 2021 Nov 18. pii: S0302-2838(21)02058.
     PubMed     Abstract available
     
     
     
176. ROBERTSON AG, Groeneveld CS, Jordan B, Lin X, et al
     Corrigendum to "Identification of Differential Tumor Subtypes of T1 Bladder Cancer" [Eur. Urol. 78 (2020) 533-537].
     Eur Urol. 2021 Nov 17. pii: S0302-2838(21)02143.
     PubMed    
     
     
     
177. PATEL SR, Lerner SP
     Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
     Eur Urol. 2021 Nov 16. pii: S0302-2838(21)02119.
     PubMed    
     
     
     
178. MIRON B, Bukavina L, Plimack ER
     Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer.
     Eur Urol. 2021 Nov 5. pii: S0302-2838(21)02121.
     PubMed    
     
     
     
179. CHOI W, Lombardo K, Patel S, Epstein G, et al
     A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2021 Nov 1. pii: S0302-2838(21)02077.
     PubMed     Abstract available
     
     
     October 2021
180. WOLDU SL, Lotan Y
     Re: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.
     Eur Urol. 2021;80:517-518.
     PubMed    
     
     
     
181. TEOH JY, Murphy DG, van Oort IM, Loeb S, et al
     Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9.
     Eur Urol. 2021;80:e101.
     PubMed    
     
     
     
182. FOERSTER B, Abufaraj M, Matin SF, Azizi M, et al
     Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
     Eur Urol. 2021;80:507-515.
     PubMed     Abstract available
     
     
     September 2021
183. BABJUK M, Burger M, Capoun O, Cohen D, et al
     European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
     Eur Urol. 2021 Sep 9. pii: S0302-2838(21)01978.
     PubMed     Abstract available
     
     
     
184. CLINTON TN
     Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01.
     Eur Urol. 2021;80:323-324.
     PubMed    
     
     
     August 2021
185. KARTOLO A, Kassouf W, Vera-Badillo FE
     Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
     Eur Urol. 2021 Aug 5. pii: S0302-2838(21)01922.
     PubMed     Abstract available
     
     
     
186. LI R, Jain RK, Sexton WJ
     Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6.
     Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01925.
     PubMed    
     
     
     
187. KESAVAN A, Esuvaranathan K
     Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
     Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01923.
     PubMed    
     
     
     
188. BEDKE J, Maas M
     Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
     Eur Urol. 2021;80:257-258.
     PubMed    
     
     
     
189. MASSON-LECOMTE A, Meria P
     Re: Complications Associated with Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
     Eur Urol. 2021;80:255.
     PubMed    
     
     
     
190. SATISH P, Kuusk T, Campain N, Abu-Ghanem Y, et al
     The European Association of Urology COVID Intermediate-priority Group is Poorly Predictive of Pathological High Risk Among Patients with Renal Tumours.
     Eur Urol. 2021;80:265-267.
     PubMed    
     
     
     
191. DELL'OGLIO P, Andras I, Ortega D, Galfano A, et al
     Impact of the Implementation of the EAU Guidelines Recommendation on Reporting and Grading of Complications in Patients Undergoing Robot-assisted Radical Cystectomy: A Systematic Review.
     Eur Urol. 2021;80:129-133.
     PubMed     Abstract available
     
     
     July 2021
192. ALFRED WITJES J
     Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
     Eur Urol. 2021;80:113.
     PubMed    
     
     
     
193. VAN DER HEIJDEN MS, Loriot Y, Duran I, Ravaud A, et al
     Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
     Eur Urol. 2021;80:7-11.
     PubMed     Abstract available
     
     
     
194. LI R, Gilbert SM, Kamat AM
     Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guerin.
     Eur Urol. 2021;80:1-3.
     PubMed     Abstract available
     
     
     June 2021
195. HU H
     Re: Richard T. Bryan, Wenyu Liu, Sarah J. Pirrie, et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol 2021;80:12-5.
     Eur Urol. 2021 Jun 29. pii: S0302-2838(21)01859.
     PubMed    
     
     
     
196. KULKARNI GS
     Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.
     Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01803.
     PubMed    
     
     
     
197. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
     Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
     Eur Urol. 2021;79:e172-e173.
     PubMed    
     
     
     
198. JONES TD, Cheng L
     Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
     Eur Urol. 2021;79:e174-e175.
     PubMed    
     
     
     May 2021
199. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
     Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
     Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
     PubMed     Abstract available
     
     
     
200. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
     Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
     Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
     PubMed    
     
     
     
201. SUNDAR S, Symonds P
     Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
     Eur Urol. 2021 May 20. pii: S0302-2838(21)00345.
     PubMed    
     
     
     
202. BRYAN RT, Catto JWF, Jefferson KP, Patel P, et al
     Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.018.
     Eur Urol. 2021 May 7. pii: S0302-2838(21)00313.
     PubMed    
     
     
     
203. PATEL SH, Kates M
     Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?
     Eur Urol. 2021;79:619-620.
     PubMed    
     
     
     
204. GAKIS G
     Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
     Eur Urol. 2021;79:702.
     PubMed    
     
     
     
205. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
     Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655-6.
     Eur Urol. 2021;79:657-658.
     PubMed    
     
     
     
206. ANDREEV-DRAKHLIN A, Gao J, Siefker-Radtke A
     Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.
     Eur Urol. 2021;79:655-656.
     PubMed    
     
     
     
207. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
     Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
     Eur Urol. 2021;79:635-654.
     PubMed     Abstract available
     
     
     April 2021
208. DURDIN T, Goh A, Pietzak E
     Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?
     Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00224.
     PubMed    
     
     
     
209. ROUMIGUIE M, Contreras-Sanz A, Black PC
     Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
     Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00234.
     PubMed    
     
     
     
210. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
     Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
     Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
     PubMed     Abstract available
     
     
     
211. JONES TD, Cheng L
     Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups.
     Eur Urol. 2021;79:489-491.
     PubMed    
     
     
     
212. FUKUOKAYA W, Egawa S
     Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
     Eur Urol. 2021;79:553-554.
     PubMed    
     
     
     
213. XU P, Chen B, Xu A, Yuan D, et al
     Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction.
     Eur Urol. 2021;79:545-551.
     PubMed     Abstract available
     
     
     March 2021
214. NECCHI A, de Jong JJ, Raggi D, Briganti A, et al
     Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
     Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00212.
     PubMed     Abstract available
     
     
     
215. GRIMM MO, Leucht K
     Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
     Eur Urol. 2021;79:429-430.
     PubMed    
     
     
     February 2021
216. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
     Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
     Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00141.
     PubMed     Abstract available
     
     
     
217. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
     The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
     Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
     PubMed     Abstract available
     
     
     
218. ABU-SALHA Y, Smith AB
     Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer.
     Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00143.
     PubMed    
     
     
     
219. GRABBERT M, Seiler R, Gratzke C
     Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial Boorjian SA, Alemozaffar M, Konety BR, et al Lancet Oncol 2021;22:107-17.
     Eur Urol. 2021 Feb 20. pii: S0302-2838(21)00099.
     PubMed    
     
     
     
220. SIGNORINI C, Maffezzini M
     Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:
     Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00075.
     PubMed    
     
     
     
221. LINDGREN MS, Jensen JB
     Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle
     Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00085.
     PubMed    
     
     
     
222. CATTO JWF, Downing A, Mason S, Wright P, et al
     Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
     Eur Urol. 2021 Feb 10. pii: S0302-2838(21)00073.
     PubMed     Abstract available
     
     
     
223. SORIA F, Gontero P
     Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.
     Eur Urol. 2021 Feb 4. pii: S0302-2838(21)00066.
     PubMed    
     
     
     
224. ALFRED WITJES J
     Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit.
     Eur Urol. 2021;79:316.
     PubMed    
     
     
     January 2021
225. LI R, Lerner SP, Kamat AM
     The Who, What, When, Where, and Why of Bacillus Calmette-Guerin-unresponsive Bladder Cancer.
     Eur Urol. 2021 Jan 13. pii: S0302-2838(21)00001.
     PubMed     Abstract available
     
     
     
226. WIJBURG CJ, Michels CTJ, Grutters JPC, Rovers MM, et al
     Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study.
     Eur Urol. 2021 Jan 11. pii: S0302-2838(20)31009.
     PubMed     Abstract available
     
     
     
227. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
     European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
     Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31019.
     PubMed     Abstract available
     
     
     
228. PERERA-BEL J, Bellmunt J
     Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.euru
     Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31024.
     PubMed    
     
     
     
229. FODE M, Jensen CFS, Ostergren PB
     How Should the Medical Community Respond to the Low Quality of Medical Information on Social Media?
     Eur Urol. 2021;79:60-61.
     PubMed    
     
     
     December 2020
230. GIANNARINI G, Valotto C, Ficarra V
     Re: Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-institutional Randomized Trial Comparing Robot Versus Open Radical Cystectomy.
     Eur Urol. 2020 Dec 19. pii: S0302-2838(20)30954.
     PubMed    
     
     
     
231. POLETAJEW S, Krajewski W, Zdrojowy R, Kryst P, et al
     Re: Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
     Eur Urol. 2020 Dec 10. pii: S0302-2838(20)30928.
     PubMed    
     
     
     
232. HUSSAIN SA, Porta N, Hall E, Salawu A, et al
     Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
     Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30937.
     PubMed     Abstract available
     
     
     
233. DE VERE WHITE R, Dall'Era M
     Re: Quality Indicators for Bladder Cancer Services: A Collaborative Review.
     Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30932.
     PubMed    
     
     
     
234. MANTICA G, Terrone C, Der Merwe AV
     Bladder Cancer and Associated Risk Factors: The African Panorama.
     Eur Urol. 2020 Dec 3. pii: S0302-2838(20)30942.
     PubMed     Abstract available
     
     
     November 2020
235. PANEBIANCO V, Del Giudice F, Narumi Y, Simone G, et al
     Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imag
     Eur Urol. 2020 Nov 28. pii: S0302-2838(20)30861.
     PubMed    
     
     
     
236. VILA-REYES H, Joel DeCastro G, McKiernan JM
     Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai,
     Eur Urol. 2020 Nov 25. pii: S0302-2838(20)30883.
     PubMed    
     
     
     
237. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
     Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
     Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
     PubMed    
     
     
     
238. BECKER REN, Baras A, Bivalacqua TJ
     Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
     Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
     PubMed    
     
     
     
239. BAKER SC, Mason AS, Southgate J
     Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer?
     Eur Urol. 2020 Nov 14. pii: S0302-2838(20)30866.
     PubMed    
     
     
     
240. MITRA AP, Miest T, Dinney CPN
     Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
     Eur Urol. 2020 Nov 3. pii: S0302-2838(20)30809.
     PubMed    
     
     
     October 2020
241. RIAZ IB, Hussain SA
     Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
     Eur Urol. 2020 Oct 1. pii: S0302-2838(20)30710.
     PubMed    
     
     
     
242. SHAH A, Tan WP, Inman BA
     National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results.
     Eur Urol. 2020;78:531-532.
     PubMed    
     
     
     
243. GRIMBERG DC, Shah A, Inman BA
     En Bloc Resection of Bladder Tumors: Style or Substance?
     Eur Urol. 2020;78:570-571.
     PubMed    
     
     
     September 2020
244. LOEB S, Reines K, Abu-Salha Y, French W, et al
     Quality of Bladder Cancer Information on YouTube.
     Eur Urol. 2020 Sep 30. pii: S0302-2838(20)30706.
     PubMed     Abstract available
     
     
     
245. LIEDBERG F, Eriksson P, Sjodahl G
     Re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048.
     Eur Urol. 2020 Sep 28. pii: S0302-2838(20)30708.
     PubMed    
     
     
     
246. MEEKS JJ, Dyrsjkot L, Robertson AG
     Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjodahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http:/
     Eur Urol. 2020 Sep 26. pii: S0302-2838(20)30722.
     PubMed    
     
     
     
247. PACKIAM VT, Bhindi B
     Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?
     Eur Urol. 2020 Sep 23. pii: S0302-2838(20)30711.
     PubMed    
     
     
     
248. TEOH JY, Huang J, Ko WY, Lok V, et al
     Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita.
     Eur Urol. 2020 Sep 21. pii: S0302-2838(20)30697.
     PubMed     Abstract available
     
     
     August 2020
249. MONTORSI F, Bandini M, Necchi A
     Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
     Eur Urol. 2020;78:e75-e76.
     PubMed    
     
     
     June 2020
250. MEEKS JJ, Robertson AG
     Immune Signatures Dominate Molecular Subtyping to Predict Response to Neoadjuvant Immunotherapy.
     Eur Urol. 2020;77:711-712.
     PubMed    
     
     
     May 2020
251. BABJUK M
     Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments?
     Eur Urol. 2020;77:581-582.
     PubMed    
     
     
     
252. MANTICA G, Terrone C
     Re: Eugene Shkolyar, Xiao Jia, Timothy C. Chang, et al. Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol 2019;76:714-8.
     Eur Urol. 2020;77:e133.
     PubMed    
     
     
     January 2020
253. KHAN MS, Omar K, Ahmed K, Gan C, et al
     Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
     Eur Urol. 2020;77:110-118.
     PubMed     Abstract available
     
     
     
254. MOSCHINI M, Shariat SF, Black P, Kamat AM, et al
     Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.
     Eur Urol. 2020;77:1-2.
     PubMed     Abstract available
     
     
     
255. VETTERLEIN MW, Klemm J, Gild P, Bradtke M, et al
     Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index.
     Eur Urol. 2020;77:55-65.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.